Navigation Links
New report calls for sustained public endorsement and funding for human stem cell research
Date:11/6/2013

A strategic report from the European Science Foundation examines the key scientific questions for human stem cell research in the context of the rapidly emerging field of regenerative medicine. In parallel to the potential new treatments for incurable diseases resulting from stem cell research, heated ethical and legal debates have arisen across the world. This report presents a comparative view of the legislative framework on human stem cell research across Europe and provides a selection of success stories in frontier research and clinical trials that underpin the advances achieved in Europe to date.

In recent years, international research on regenerative medicine and stem cells has yielded some promising results and even greater expectations in society. In this medical field, human embryonic stem cells could be applied in a variety of ways, for example to identify new compounds for drug development, or as cell-based therapies. The potential to use human stem cells to repair or replace tissue or organ functions lost through age, disease, damage or birth defects may raise ethical issues that must be considered integrally with any research. Europe is currently witnessing developments and debates that will impact regulation and public funding of stem cell research and innovation for years to come.

The report observes that Europe plays a leading role in regenerative medicine research, with most countries featuring legislative frameworks that are globally favourable to human stem cell research. The 30 countries' position on human stem cell research was grouped into five broad categories; very permissive, permissive with restrictions, restrictive by default, very restrictive and unlegislated. The report found that 63% of the countries fell into the first two categories.

"Europe has a valuable track record in the area of stem cell research. The report highlights the need to continue to fund this research so that its full potential can be realised." said Professor Stig Slrdahl, Dean of the Faculty of Medicine at Norwegian University of Science and Technology, who chaired the report.

The authors recommend that sustained public endorsement and funding need to continue in order for further research to be carried out and public-private partnerships to develop, bringing safe and innovative therapies to the market, with a potential benefit to millions of patients worldwide.

Dr Vanessa Campo-Ruiz, ESF Science Officer to the Chief Executive and lead author of the report commented: "We hope this report may help to inform future policy and funding decisions across Europe and thus contribute to ensure this continent's scientific leadership, social welfare and economic growth."


'/>"/>

Contact: Emma Knott
esf@kaizo.co.uk
44-203-176-4715
European Science Foundation
Source:Eurekalert

Related medicine news :

1. Young girls more likely to report side effects after HPV vaccine
2. Preteens More Likely to Report HPV Vaccine Side Effects
3. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
4. Report says new evidence could tip the balance in aspirin cancer prevention care
5. U.S. Spends Too Little on Public Health Initiatives: Report
6. NJ stroke researchers report advances in spatial neglect research at AAN Conference
7. Mental Illness Tied to Higher Rates of Physical Problems: Report
8. Diagnostic yield of colonoscopy for melena after nondiagnostic upper endoscopy is lower than previously reported
9. Report outlines successes, challenges in cancer prevention efforts
10. Healthy Lifestyle Choices Could Cut Cancer Rates: Report
11. On-the-job deaths steady in Michigan; Number of burn injuries underreported
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology: